Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis | Zendy

Henry M. Staines | Zendy; Rebekah Burrow | Zendy; Beatrix Huei-Yi Teo | Zendy; Irina Chis Ster | Zendy; Peter G. Kremsner | Zendy; Sanjeev Krishna | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis

Author(s) -

Henry M. Staines,

Rebekah Burrow,

Beatrix Huei-Yi Teo,

Irina Chis Ster,

Peter G. Kremsner,

Sanjeev Krishna

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx431

Subject(s) - atovaquone , proguanil , malaria , plasmodium falciparum , medicine , population , cytochrome b , biology , genetics , immunology , environmental health , mitochondrial dna , gene

Atovaquone/proguanil, registered as Malarone®, is a fixed-dose combination recommended for first-line treatment of uncomplicated Plasmodium falciparum malaria in non-endemic countries and its prevention in travellers. Mutations in the cytochrome bc1 complex are causally associated with atovaquone resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research